Clinical Trials/NCT05952206

NCT05952206Active, not recruitingPhase 3

Ischemic and Bleeding Outcomes After Angiolite Stent Implantation and an Abbreviated Dual Antiplatelet Therapy. A 2x2 Factorial, All-comer, Multicenter, Randomized Controlled Trial: ANGIODAPT

iVascular S.L.U.77 sites in 3 countries2,312 target enrollmentStarted: October 13, 2023Last updated: May 15, 2026

Conditions

Interventions

Drugs

Trial Snapshot

Phase: Phase 3
Status: Active, not recruiting
Sponsor
Enrollment: 2,312
Locations: 77
Primary Endpoint: To determine the rate of target lesion failure between angiolite stent and Xience stent family (tested for non-inferiority) in both the standard of care DAPT regimen and abbreviated antiplatelet therapy group.

Study Overview Study Design Eligibility Criteria Arms & Interventions Outcomes Investigators Sites Records & Identifiers Similar Trials

Study Overview

Brief Summary

Factorial 2x2, all-comer, multicentre, randomized controlled trial (ratio 1:1:1:1). First, the study will compare (first randomization) the non-inferiority in target lesion failure of angiolite stent versus Xience stent family. Immediately after the first randomization, the study compares (second randomization) the superiority in bleeding Bleeding Academic Research Consortium (BARC) 2, 3, or 5 of abbreviated DAPT versus standard of care. Both primary endpoints will be evaluated at 12 months of follow-up. The study will be open-label for the stent type and the antiplatelet regimen.

Study Design

Study Type: Interventional
Allocation: Randomized
Intervention Model: Factorial
Primary Purpose: Treatment
Masking: None (Participant, Outcomes Assessor)

Masking Description

Masking:

Open-label for the stent type
Open-label for the antiplatelet regimen

Eligibility Criteria

Ages: 18 Years to 95 Years (Adult, Older Adult)
Sex: All
Accepts Healthy Volunteers: No

Inclusion Criteria

•Age >18 - < 95 years;
•Presence of one or more coronary artery stenosis of 50% or more in a native coronary artery or in a saphenous venous or arterial bypass conduit suitable for coronary stent implantation. The vessel should have a reference vessel diameter of at least 2.00 mm (no limitation on the number of treated lesions, vessels, or lesion length);
•Able to provide informed consent and willing to participate in the trial.

Exclusion Criteria

•Known intolerance to acetylsalicylic acid, P2Y12 inhibitors (clopidogrel, prasugrel, or ticagrelor), sirolimus, everolimus, or chromium-cobalt.;
•Known severe hepatic impairment Child-Pug stage C;
•Prior PCI (not related to the study) performed in the last 45 days;
•Planned non-cardiac surgery during the first month after PCI, unless dual antiplatelet therapy is maintained throughout the peri-surgical period;
•Planned coronary artery bypass graft (CABG) or any other cardiac surgery (valvular for instance) following index PCI;
•Active major bleeding or major surgery within the last 30 days;
•Known stroke (any type) within the 30 days prior to the randomization;
•Women of childbearing potential being defined as woman from the onset of menstruation (menarche) until they become postmenopausal, unless they are permanently sterile. A postmenopausal state is clarified as having no menstrual periods for 12 consecutive months without any other medical cause. Women who have undergone permanent sterilization methods, including hysterectomy, bilateral salpingectomy, and bilateral oophorectomy, can be enrolled in the study
•Currently participating in another randomized controlled trial and not yet at its primary endpoint;
•Life expectancy less than one year due to non-cardiovascular comorbidity.

Arms & Interventions

Angiolite and abbreviated DAPT

Experimental

Acute coronary syndrome patients:

Need for OAC: TAT + OAC for one week. Double therapy composed of clopidogrel + OAC up to 6 months.
No need for OAC: DAPT with acetylsalicylic acid + prasugrel or ticagrelor for 1M. Only the same P2Y12 inhibitor up to 12M.

Chronic coronary syndrome patients:

Need for OAC: TAT + clopidogrel + OAC for one week. Double therapy composed of clopidogrel + OAC up to 6M.
No need for OAC: DAPT with acetylsalicylic acid + clopidogrel for one month. Only clopidogrel up to 12M.

Intervention: 1-month DAPT (Drug)

Xience stent family and abbreviated DAPT

Experimental

Acute coronary syndrome patients:

Need for OAC: TAT + OAC for one week. Double therapy composed of clopidogrel + OAC up to 6M.
No need for OAC: DAPT with acetylsalicylic acid + prasugrel or ticagrelor for 1 month. Only the same P2Y12 inhibitor up to 12M.

Chronic coronary syndrome patients:

Need for OAC: TAT + clopidogrel + OAC for one week. Double therapy composed of clopidogrel + OAC up to 6M.
No need for OAC: DAPT with acetylsalicylic acid + clopidogrel for one month. Only clopidogrel up to 12M.

Intervention: 1-month DAPT (Drug)

Angiolite and standard of care DAPT

Active Comparator

Acute coronary syndrome patients:

Need for OAC: Recommendations of the current ESC guideline: 1M of TAT (acetylsalicylic acid + clopidogrel + OAC). Dual therapy (acetylsalicylic acid or clopidogrel + OAC) up to 12M. If ischemic concerns prevail, TAT can be extended up to 6M and dual therapy up to 12M.
No need for OAC: Recommendations of the current ESC guideline: DAPT with acetylsalicylic acid and prasugrel or ticagrelor is recommended up to 12M.

Chronic coronary syndrome:

Need for OAC: Recommendations of the current ESC guidelines: 1M of TAT (acetylsalicylic acid + clopidogrel + OAC). Dual therapy (acetylsalicylic acid or clopidogrel + OAC) up to 12M. If ischemic concerns prevail, TAT can be extended up to 6M and dual therapy up to 12M.
No need for OAC: Recommendations of the current ESC guidelines: DAPT composed of acetylsalicylic acid + clopidogrel up to 6M. Then, continue with acetylsalicylic acid.

Intervention: 12-month DAPT (Standard of care) (Drug)

Xience stent family and standard of care DAPT

Active Comparator

Acute coronary syndrome patients:

Need for OAC: Recommendations of the current ESC guideline: 1M of TAT (acetylsalicylic acid + clopidogrel + OAC). Dual therapy (acetylsalicylic acid or clopidogrel + OAC) up to 12M. If ischemic concerns prevail, TAT can be extended up to 6M and dual therapy up to 12M.
No need for OAC: Recommendations of the current ESC guideline: DAPT with acetylsalicylic acid and prasugrel or ticagrelor is recommended up to 12M.

Chronic coronary syndrome:

Need for OAC: Recommendations of the current ESC guidelines: 1M of TAT (acetylsalicylic acid + clopidogrel + OAC). Dual therapy (acetylsalicylic acid or clopidogrel + OAC) up to 12M. If ischemic concerns prevail, TAT can be extended up to 6M and dual therapy up to 12M.
No need for OAC: Recommendations of the current ESC guidelines: DAPT composed of acetylsalicylic acid + clopidogrel up to 6M. Then, continue with acetylsalicylic acid.

Intervention: 12-month DAPT (Standard of care) (Drug)

Outcomes

Primary Outcomes

To determine the rate of target lesion failure between angiolite stent and Xience stent family (tested for non-inferiority) in both the standard of care DAPT regimen and abbreviated antiplatelet therapy group.

Time Frame: 1 year

To determine the rate of clinically relevant bleeding events (BARC 2, 3, or 5) between an abbreviated DAPT regimen and the standard of care DAPT (tested for superiority of the experimental arm).

Time Frame: 1 year

Secondary Outcomes

To determine the rate of adverse ischemic events between an abbreviated dual antiplatelet therapy regimen and the standard of care dual antiplatelet therapy (tested for non-inferiority).(1 year)
Rate of target lesion failure between angiolite stent and Xience stent family (Skypoint or Sierra) (tested for non-inferiority) in the standard of care subgroup.(1 year)

Investigators

Sponsor

iVascular S.L.U.

Sponsor Class

Industry

Responsible Party

Sponsor

Study Sites (77)

Loading locations...

Similar Trials

Recruiting

Phase 1

Study to evaluate reduced antiplatelet therapy after angiolite stent implantation in patients with coronary artery diseaseCoronary Artery DiseaseMedDRA version: 20.0Level: PTClassification code: 10011078Term: Coronary artery disease Class: 100000004849

CTIS2023-507015-35-00Ivascular S.L.2,932

Completed

Phase 4

Dual Antiplatelet Therapy Versus Oral Anticoagulation for a Short Time to Prevent Cerebral Embolism After TAVIAortic Valve StenosisStroke

NCT01642134Andres Iñiguez Romo, MD, PhD124

Active, not recruiting

Not Applicable

Acute STEMI treated with primary angioplasty and intravenous enoxaparin orUFH to lower ischemic and bleeding events at short- and long-term follow-up. - ATO

EUCTR2007-007676-42-DEASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)910

Active, not recruiting

Not Applicable

Acute STEMI treated with primary angioplasty and intravenous enoxaparin orUFH to lower ischemic and bleeding events at short- and long-term follow-up. - ATORandomized evaluation of enoxaparin versus unfractioned heparine (UFH) withGPIIb/IIIa inhibitors70-100IU without GPIIb/IIIa inhibitors) in patients showing an acute ST elevation myocardial Infarction (STEMI). All STEMIs will be treated by fibrinolysis followed by a percutaneous transluminal coronary intervention (PCI).MedDRA version: 9.1Level: LLTClassification code 10064345Term: ST segment elevation myocardial infarction

EUCTR2007-007676-42-ATASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)910

Unknown

Not Applicable

The European Bifurcation Club Left Main StudyPercutaneous Transluminal Coronary AngioplastyCoronary Artery Disease

NCT02497014European Cardiovascular Research Center450